Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study
- 266 Downloads
Type 2 diabetes (DM2) is associated to oxidative modifications of high-density lipoproteins (HDL), which can interfere with their function. Pioglitazone has proved effective in raising HDL cholesterol (HDL-C) and lowering small dense low-density lipoprotein (LDL), but no clinical studies have examined its effect on lipoprotein oxidation in patients with DM2.
We assessed the effect of pioglitazone vs glimepiride after 1 year on HDL oxidation, expressed as relative abundance of peptides containing Met112O in ApoA-I (oxApoA-I) estimated by mass spectrometry (MALDI/TOF/TOF), in 95 patients with DM2. The oxLDL and AGE were quantified by ELISA.
Patients receiving pioglitazone showed a significant increase in the concentration of ApoA-I (Δ = 7.2 ± 14.8 mg/dL, p < 0.02) and a reduction in oxApoA-I (Δ = − 1.0 ± 2.6%, p < 0.02); this reduction was not significantly different from glimepiride. oxLDL showed a slight, but not significant increase in both treatment groups. Regression analysis showed a correlation between ΔoxApoA-I and ΔAGE (r = 0.30; p = 0.007) in all patients, while both of these parameters were unrelated to changes in HbA1c, HDL-C, duration of illness, or use of statins.
Long-term treatment with pioglitazone was effective in reducing the oxidation of HDL, but not LDL in patients with DM2, while glimepiride didn’t. This finding seems to be associated to the change of glyco-oxidation status, not to any improvement in glycemic control or lipid profile.
NCT00700856, ClinicalTrials.gov Registered June 18, 2008
KeywordsClinical trials Diabetes Mass spectrometry Oxidized lipids Lipoproteins
NCC wrote the manuscript. GS contributed to study design. NCC, SB, GS researched and analyzed data. AL edited and reviewed manuscript. OV contributed to the discussion. ER contributed to data access and statistical support. RS, RM, MR, CC contributed to data collection and performed the relevant laboratory measurements. All authors read and approved the final version to be published.
This research was supported by the Italian Medicines Agency (AIFA) as part of the Independent Drug Research Program (contract N°. FARM6T9CET), and by Diabete Ricerca, the not-for-profit Research Foundation of the Italian Diabetes Society.
Compliance with ethical standards
Conflict of interest
The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Wilson PW, Abbott RD, Castelli WP (1988) High-density lipoprotein cholesterol and mortality. Framingham Heart Study Arterioscler 8:737–741Google Scholar
- 5.Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J et al (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51(1):123–131CrossRefPubMedGoogle Scholar
- 14.Mirmiranpour H, Mousavizadeh M, Noshad S, Ghavami M, Ebadi M, Ghasemiesfe M et al (2013) Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial. J Diabetes Complicat 27:501–507CrossRefPubMedGoogle Scholar
- 15.Koyama H, Tanaka S, Monden M, Shoji T, Morioka T, Fukumoto S et al (2014) Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). Atherosclerosis 234:329–334CrossRefPubMedGoogle Scholar
- 19.Vaccaro O, Masulli M, Bonora E, Prato SD, Giorda CB, Maggioni AP et al (2012) Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. Nutr Metab Cardiovasc Dis 22:997–1006CrossRefPubMedGoogle Scholar
- 25.Schumaker VN, Puppione DL (1986) Sequential flotation ultracentrifugation. Methods Enzymol 128:155e70Google Scholar
- 26.Hainline A, Karon J, Lippel K (1982) Lipid research clinics program: lipid and lipoprotein analysis. In: Hainline A, Karon J, Lippel K (eds) Manual of laboratory operations. US Dept Health and Human Services, Washington, DC, pp 63–77Google Scholar
- 30.Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. PNAS 105:1224–1229Google Scholar
- 31.Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 1279–1289CrossRefPubMedGoogle Scholar
- 33.Mariz S, Urquhart R, Moules I, Tan MH, Edwards G (2004) Effects of pioglitazone addition to metformin or sulfonylurea therapy on serum lipids in patients with type 2 diabetes mellitus: 2-year data. Diabetes 53:578PGoogle Scholar
- 35.Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56(10):2153–2163CrossRefPubMedGoogle Scholar